Finance

Beta
Lists
ATRA:NASDAQ
Atara Biotherapeutics Inc
$11.48
+2.78%
(+0.31) 1D
$11.48
0.00% (0.00)
After hours
Closed: Jun 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATRA...
Open
$11.11
High
$11.63
Low
$11.01
Mkt. cap
103.44M
Avg. vol.
114.70K
Volume
106.74K
52-wk high
$19.14
52-wk low
$3.92
EPS
-$0.86
Beta
0.11
Shares outstanding
9.01M
No. of employees
13
Open
$11.11
High
$11.63
Low
$11.01
Mkt. cap
103.44M
Avg. vol.
114.70K
Volume
106.74K
52-wk high
$19.14
52-wk low
$3.92
EPS
-$0.86
Beta
0.11
Shares outstanding
9.01M
No. of employees
13
News stories
From sources across the web
About Atara Biotherapeutics Inc
CEO-
Employees13
Founded2012
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteatarabio.com
Analyst ratings
Based on 3 analysts giving stock ratings to ATRA in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for ATRA in the last 3 months.
Highest
Current $11.48
$18.00 (+56.79%)
Average
$13.67 (+19.08%)
Lowest
$10.00 (-12.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Salim Syed
Mizuho Securities
Buy
Maintained
$18.00
+56.8%
06/18/2026
Ilya Zubkov
Freedom Capital Markets
Hold
Upgraded
$10.00
-12.9%
05/18/2026
John Newman
Canaccord Genuity
Buy
Maintained
$13.00
+13.2%
05/13/2026
Last report
May 12, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.29 / -$0.22
-33.84%miss
Revenue / Est. (USD)
516.00K / 2.18M
-76.28%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
17.58M
3.45M
1.60M
516.00K
Cost of goods sold
6.92M
3.02M
783.00K
288.00K
Cost of revenue
6.92M
3.02M
783.00K
288.00K
Research and development expenses
-
-
2.86M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.94M
3.98M
3.37M
3.60M
Operating expense
5.94M
3.98M
6.23M
3.60M
Total operating expenses
12.86M
7.00M
7.01M
3.88M
Operating income
4.72M
-3.55M
-5.42M
-3.37M
Other non operating income
22.00K
4.00K
-49.00K
-
EBT including unusual items
2.39M
-4.28M
-3.41M
-4.14M
EBT excluding unusual items
3.91M
-4.25M
-6.26M
-4.14M
Income tax expense
3.00K
28.00K
-
-
Effective tax rate
0.13%
-0.65%
-
-
Other operating expenses
-
-
-
-
Net income
2.39M
-4.30M
-3.41M
-4.14M
Net profit margin
13.58%
-124.62%
-213.54%
-803.29%
Earnings per share
0.19
-0.32
-0.35
-0.29
Interest and investment income
143.00K
204.00K
100.00K
54.00K
Interest expense
-972.00K
-909.00K
-894.00K
-830.00K
Net interest expenses
-829.00K
-705.00K
-794.00K
-776.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
5.62M
-3.19M
-4.37M
-3.34M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer